Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Breast and Gastric Cancer In Vitro and In Vivo Models

Current protocols Pub Date : 2025-03-03 DOI:10.1002/cpz1.70113

Feng Tang, Hong Xu, Wen Cui, Xuelin Wang, Fangyi Ding, Yihan Zhang, Xiangnan Qiang, Qingyang Gu, Dong Wang, Zhixiang Zhang

{"title":"Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Breast and Gastric Cancer In Vitro and In Vivo Models","authors":"Feng Tang, Hong Xu, Wen Cui, Xuelin Wang, Fangyi Ding, Yihan Zhang, Xiangnan Qiang, Qingyang Gu, Dong Wang, Zhixiang Zhang","doi":"10.1002/cpz1.70113","DOIUrl":null,"url":null,"abstract":"Paclitaxel, one of the most commonly used anticancer agents, is employed in the treatment of a range of malignant tumors. However, resistance is one of the major barriers to successful therapy. Despite its clinical relevance, the molecular mechanisms underlying paclitaxel resistance remain poorly understood. In this protocol, we describe the methods for establishing paclitaxel-resistant tumor models both in vitro and in vivo, and how we investigated the underlying mechanisms of resistance. Additionally, we evaluated the potential of combination therapies to overcome paclitaxel resistance in these models. © 2025 Wiley Periodicals LLC.Basic Protocol 1: Generation of paclitaxel-resistant breast cancer model in vivo.Basic Protocol 2: Generation of paclitaxel-resistant gastric cancer model in vitro.Basic Protocol 3: Validation of drug resistance in vivo.Basic Protocol 4: In vitro and in vivo evaluation of combination therapy in paclitaxel-resistant models.","PeriodicalId":93970,"journal":{"name":"Current protocols","volume":"5 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protocols","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpz1.70113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Paclitaxel, one of the most commonly used anticancer agents, is employed in the treatment of a range of malignant tumors. However, resistance is one of the major barriers to successful therapy. Despite its clinical relevance, the molecular mechanisms underlying paclitaxel resistance remain poorly understood. In this protocol, we describe the methods for establishing paclitaxel-resistant tumor models both in vitro and in vivo, and how we investigated the underlying mechanisms of resistance. Additionally, we evaluated the potential of combination therapies to overcome paclitaxel resistance in these models. © 2025 Wiley Periodicals LLC.

Basic Protocol 1: Generation of paclitaxel-resistant breast cancer model in vivo.

Basic Protocol 2: Generation of paclitaxel-resistant gastric cancer model in vitro.

Basic Protocol 3: Validation of drug resistance in vivo.

Basic Protocol 4: In vitro and in vivo evaluation of combination therapy in paclitaxel-resistant models.

查看原文本刊更多论文

紫杉醇耐药乳腺癌和胃癌体外和体内模型的发展、表征和治疗应用

紫杉醇是最常用的抗癌药物之一，被用于治疗各种恶性肿瘤。然而，耐药性是成功治疗的主要障碍之一。尽管紫杉醇耐药性与临床息息相关，但人们对其分子机制仍然知之甚少。在本方案中，我们介绍了在体外和体内建立紫杉醇耐药肿瘤模型的方法，以及如何研究耐药的内在机制。此外，我们还评估了联合疗法在这些模型中克服紫杉醇耐药性的潜力。© 2025 Wiley Periodicals LLC.Basic Protocol 1: Generation of paclitaxel-resistant breast cancer model in vivo.Basic Protocol 2: Generation of paclitaxel-resistant gastric cancer model in vitro.Basic Protocol 3: Validation of drug resistance in vivo.Basic Protocol 4: In vitro and in vivo evaluation of combination therapy in paclitaxel-resistant models.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current protocols

CiteScore

4.00

自引率

0.00%

发文量